PMID- 22974412
OWN - NLM
STAT- MEDLINE
DCOM- 20130619
LR  - 20240317
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Print)
IS  - 1520-9156 (Linking)
VI  - 14
IP  - 12
DP  - 2012 Dec
TI  - Effect of metformin glycinate on glycated hemoglobin A1C concentration and 
      insulin sensitivity in drug-naive adult patients with type 2 diabetes mellitus.
PG  - 1140-4
LID - 10.1089/dia.2012.0097 [doi]
AB  - AIM: This study evaluated the effect of metformin glycinate on glycated 
      hemoglobin A1c (A1C) concentration and insulin sensitivity in drug-naive adult 
      patients with type 2 diabetes mellitus (T2DM). SUBJECTS AND METHODS: A 
      randomized, double-blind, placebo-controlled clinical trial was carried out in 20 
      patients with drug-naive T2DM. Ten subjects received metformin glycinate (1,050.6 
      mg) once daily during the first month and force-titrated twice daily during the 
      second month. Ten additional patients received placebo as the control group. 
      Before and after the intervention, metabolic profile including A1C and insulin 
      sensitivity (euglycemic-hyperinsulinemic clamp technique) was estimated. RESULTS: 
      A1C concentrations decreased significantly with metformin glycinate 
      administration (8.0 +/- 0.7% vs. 7.1 +/- 0.9%, P = 0.008) before and after the 
      intervention, respectively. There were significant differences in changes from 
      baseline of A1C between groups (0.0 +/- 0.7% vs. -1.0 +/- 0.5% for placebo and 
      metformin glycinate groups, respectively; P = 0.004). A reduction of >/=1% in A1C 
      levels was reached in 60.0% of patients with metformin glycinate administration 
      (P = 0.02). Insulin sensitivity was not modified by the intervention. 
      CONCLUSIONS: Administration of metformin glycinate during a 2-month period showed 
      a greater decrease in A1C concentrations than placebo in a selected group of 
      drug-naive adult patients with T2DM.
FAU - Gonzalez-Ortiz, Manuel
AU  - Gonzalez-Ortiz M
AD  - Cardiovascular Research Unit, Physiology Department, Health Science University 
      Center, University of Guadalajara, Guadalajara, Mexico.
FAU - Martinez-Abundis, Esperanza
AU  - Martinez-Abundis E
FAU - Robles-Cervantes, Jose A
AU  - Robles-Cervantes JA
FAU - Ramos-Zavala, Maria G
AU  - Ramos-Zavala MG
FAU - Barrera-Duran, Carmelita
AU  - Barrera-Duran C
FAU - Gonzalez-Canudas, Jorge
AU  - Gonzalez-Canudas J
LA  - eng
SI  - ClinicalTrials.gov/NCT00940797
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120913
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adult
MH  - Algorithms
MH  - Blood Glucose/*drug effects/metabolism
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/epidemiology
MH  - Double-Blind Method
MH  - Female
MH  - Glucose Clamp Technique
MH  - Glycated Hemoglobin/*drug effects/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*pharmacology/therapeutic use
MH  - *Insulin Resistance
MH  - Male
MH  - Metformin/*pharmacology/therapeutic use
MH  - Mexico/epidemiology
MH  - Middle Aged
MH  - Treatment Outcome
PMC - PMC3521136
EDAT- 2012/09/15 06:00
MHDA- 2013/06/20 06:00
PMCR- 2012/12/01
CRDT- 2012/09/15 06:00
PHST- 2012/09/15 06:00 [entrez]
PHST- 2012/09/15 06:00 [pubmed]
PHST- 2013/06/20 06:00 [medline]
PHST- 2012/12/01 00:00 [pmc-release]
AID - 10.1089/dia.2012.0097 [pii]
AID - 10.1089/dia.2012.0097 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2012 Dec;14(12):1140-4. doi: 10.1089/dia.2012.0097. Epub 
      2012 Sep 13.